Abstract:Mounting evidence suggests a prominent role for alpha-synuclein (a-syn) in neuronal cell function. Alterations in the levels of cellular a-syn have been hypothesized to play a critical role in the development of Parkinson's disease (PD); however, mechanisms that control expression of the gene for a-syn ( SNCA ) in cis and trans as well as turnover of a-syn are not well understood. We analyzed whether methyl-CpG binding protein 2 (MeCP2), a protein that specifically binds methylated DNA, thus regulating transcription, binds at predicted binding sites in intron 1 of the SNCA gene and regulates a-syn protein expression Chromatin immunoprecipitation (ChIP) and electrophoretic mobility-shift assays (EMSA) were used to confirm binding of MeCP2 to regulatory regions of SNCA . Site-specific methylation and introduction of localized mutations by CRISPR/Cas9 were used to investigate the binding properties of MeCP2 in human SK-N-SH neuroblastoma cells. The significance of MeCP2 for SNCA regulation was further investigated by overexpressing MeCP2 and mutated variants of MeCP2 in MeCP2 knockout cells. We found that methylation-dependent binding of MeCP2 at a restricted region of intron 1 of SNCA had a significant impact on the production of a-syn. A single nucleotide substitution near to CpG1 strongly increased the binding of MeCP2 to intron 1 of SNCA and decreased a-syn protein expression by 60%. In contrast, deletion of a single nucleotide closed to CpG2 led to reduced binding of MeCP2 and significantly increased a-syn levels. In accordance, knockout of MeCP2 in SK-N-SH cells resulted in a significant increase in a-syn production, demonstrating that SNCA is a genomic target for MeCP2 regulation. In addition, the expression of two mutated MeCP2 variants found in Rett syndrome (RTT) showed a loss of their ability to reduce a-syn expression. This study demonstrates that methylation of CpGs and binding of MeCP2 to intron 1 of the SNCA gene plays an important role in the control of a-syn expression. In addition, the changes in SNCA regulation found by expression of MeCP2 variants carrying mutations found in RTT patients may be of importance for the elucidation of a new molecular pathway in RTT, a rare neurological disorder caused by mutations in MECP2 .

Human MeCP2 binds to promoters and inhibits transcription in an unmethylated S. cerevisiae genome

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

Differential dynamics specify MeCP2 function at nucleosomes and methylated DNA

SUMOylation of MeCP2 is essential for transcriptional repression and hippocampal synapse development.

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

MeCP2 and neurodevelopmental disorders

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons

The methyl-CpG-binding domain (MBD) is crucial for MeCP2's dysfunction-induced defects in adult newborn neurons.

Emerging physiological and pathological roles of MeCP2 in non-neurological systems

Extending MeCP2 interactome: canonical nucleosomal histones interact with MeCP2

MeCP2 links heterochromatin condensates and neurodevelopmental disease

Transcriptional Inhibition of the Mecp2 Promoter by MeCP2E1 and MeCP2E2 Isoforms Suggests Negative Auto-Regulatory Feedback that can be Moderated by Metformin

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

The Alpha-Synuclein Gene (SNCA) is a Genomic Target of Methyl-CpG Binding Protein 2 (MeCP2)—Implications for Parkinson's Disease and Rett Syndrome

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels